<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="369651">
  <stage>Registered</stage>
  <submitdate>19/11/2015</submitdate>
  <approvaldate>24/11/2015</approvaldate>
  <actrnumber>ACTRN12615001277538</actrnumber>
  <trial_identification>
    <studytitle>Vitamin C for Colorectal Cancer: A clinical window study to assess high dose vitamin C administration in colorectal cancer patients</studytitle>
    <scientifictitle>A clinical window study in colorectal cancer patients to assess the effects of high dose vitamin C administration on tumour biology</scientifictitle>
    <utrn>U1111-1173-0882 </utrn>
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Colorectal cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Bowel - Back passage (rectum) or large bowel (colon)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Participants will receive a high dose vitamin C infusion (1g vitamin C/kg body weight) each day for four days prior to surgical resection of tumour. All infusions will be administered by research nurse.</interventions>
    <comparator>Control group will receive no high dose vitamin C intervention prior to surgery.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Ascorbate uptake - plasma, normal colon tissue, tumour tissue (measured by HPLC with electrochemical detection) - composite primary outcome</outcome>
      <timepoint>Treatment group: at diagnostic colonoscopy (blood and tissue), prior to each of four daily vitamin C infusions (blood), following surgical resection of tumour (tissue)

Control group: at diagnostic colonoscopy (blood and tissue), prior to surgery (blood), following surgical resection of tumour (tissue)
</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Changes in tumour biology - HIF-1 protein levels/activity i.e. downstream gene expression e.g. VEGF, GLUT-1, BNIP3, CAIX (measured by Western blotting and ELISA)</outcome>
      <timepoint>Tissue taken at diagnostic colonoscopy and tumour resection</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Changes in tumour histopathology e.g. vitamin C transporter status, immune infiltrate, micro-vessel density (measured by immunohistochemistry)</outcome>
      <timepoint>Tissue taken at diagnostic colonoscopy and tumour resection</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Changes in markers of inflammation e.g. plasma CRP, TNF, IL-6 (measured by immunoassay and ELISA)</outcome>
      <timepoint>Blood taken at diagnostic colonoscopy and day prior to surgery</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Changes in chromosome modifications (measured by ELISA)</outcome>
      <timepoint>Tissue taken at diagnostic colonoscopy and tumour resection</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Patient quality of life (measured by questionnaires e.g. EORTC-QLQ, MFSI, VAS)</outcome>
      <timepoint>At diagnostic colonoscopy, day before surgery, and at six weeks, three months, six months post surgery</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Wound healing i.e. whether wound healed with or without infection, as diagnosed by treating physician</outcome>
      <timepoint>At six weeks, three months, six months post surgery</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Feasibility of study e.g. patient accrual rate and patient acceptance of schedule (Likert scale survey)</outcome>
      <timepoint>At six weeks post surgery</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1.	Confirmed colorectal cancer (via biopsy histology) and scheduled to undergo surgery
2.	Good physical functional status  ECOG grade 0 or 1
3.	Aged &gt;/= 18 years
4.	Able to give informed consent to participate in the study
5.	Signed informed consent to donate tissue (biopsy tissue and surplus tissue from surgery) and blood samples
6.	Adequate bone marrow, hepatic, renal and cardiac function
7.	Able to come to the clinical research unit four times in the week prior to surgery for IV infusions
</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1.	Receiving neoadjuvant therapy
2.	Supplementing with vitamin C &gt;/= 1g/d
3.	Serum creatinine concentration &gt;175 Âµmol/L
4.	Erythrocyte glucose-6-phosphate dehydrogenase activity deficiency
5.	Serious gastrointestinal disorders including active bleeding
6.	Patients with serious or uncontrolled infection, cardiac or neurological conditions
7.	Dementia or altered mental status that would render informed consent impossible
8.	Pregnant or lactating women
9.	Any abnormal laboratory value or medical condition that would, in the investigators judgement, make the patient a poor candidate for the study
10.	Current calcium oxalate nephropathies with the potential to block urinary flow
11.	Adverse response to test dose of 25 g IV vitamin C given on the first intervention day
12.	Individuals with diabetes as HDVC can have a hypoglycaemic effect and can also interfere with some glucose finger stick devices
</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>14/12/2015</anticipatedstartdate>
    <actualstartdate>23/03/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate>12/12/2016</actualenddate>
    <samplesize>12</samplesize>
    <actualsamplesize>15</actualsamplesize>
    <currentsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>21/12/2016</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Canterbury</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Prof Margreet Vissers</primarysponsorname>
    <primarysponsoraddress>University of Otago, Christchurch
PO Box 4345
Christchurch 8140</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Health Resarch Council of New Zealand</fundingname>
      <fundingaddress>Level 3
110 Stanley St
Grafton
Auckland 1010</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The aim of this study is to carry out a clinical window study in patients with colorectal cancer to determine whether vitamin C administered intravenously (high dose vitamin C) can reach tumours and produce measureable changes in tumour biology. </summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Southern Health and Disability Ethics Committee</ethicname>
      <ethicaddress>Ministry of Health
Freyberg Building
PO Box 5013
Wellington 6011</ethicaddress>
      <ethicapprovaldate>23/09/2015</ethicapprovaldate>
      <hrec>15/STH/145</hrec>
      <ethicsubmitdate>28/08/2015</ethicsubmitdate>
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Margreet Vissers</name>
      <address>University of Otago, Christchurch
PO Box 4345
Christchurch 8140</address>
      <phone>64 3 364 1524</phone>
      <fax />
      <email>margreet.vissers@otago.ac.nz</email>
      <country>New Zealand</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Margreet Vissers</name>
      <address>University of Otago, Christchurch
PO Box 4345
Christchurch 8140</address>
      <phone>64 3 364 1524</phone>
      <fax />
      <email>margreet.vissers@otago.ac.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Margreet Vissers</name>
      <address>University of Otago, Christchurch
PO Box 4345
Christchurch 8140</address>
      <phone>64 3 364 1524</phone>
      <fax />
      <email>margreet.vissers@otago.ac.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Anitra Carr</name>
      <address>University of Otago, Christchurch
PO Box 4345
Christchurch 8140</address>
      <phone>64 3 364 0649</phone>
      <fax />
      <email>anitra.carr@otago.ac.nz</email>
      <country>New Zealand</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>